Sargent Investment Group’s Cytosorbents Corp CTSO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $208K | Buy |
27,788
+293
| +1% | +$3.1K | 0.03% | 260 |
|
|
2026
Q1 | $311K | Sell |
27,495
-3,105
| -10% | -$42.4K | 0.04% | 202 |
|
|
2025
Q4 | $391K | Sell |
30,600
-6,335
| -17% | -$97.5K | 0.05% | 184 |
|
|
2025
Q3 | $690K | Sell |
36,935
-375
| -1% | -$7.39K | 0.1% | 99 |
|
|
2025
Q2 | $673K | Sell |
37,310
-3,865
| -9% | -$77.6K | 0.09% | 134 |
|
|
2025
Q1 | $824K | Sell |
41,175
-21,268
| -34% | -$448K | 0.13% | 109 |
|
|
2024
Q4 | $1.31M | Sell |
62,443
-18,869
| -23% | -$370K | 0.21% | 85 |
|
|
2024
Q3 | $2.44M | Buy |
81,312
+9,637
| +13% | +$211K | 0.44% | 48 |
|
|
2024
Q2 | $1.01M | Buy |
71,675
+3,359
| +5% | +$58.3K | 0.21% | 81 |
|
|
2024
Q1 | $1.3M | Buy |
68,316
+2,879
| +4% | +$56K | 0.28% | 68 |
|
|
2023
Q4 | $1.45M | Buy |
65,437
+2,585
| +4% | +$76.8K | 0.32% | 64 |
|
|
2023
Q3 | $2.36M | Sell |
62,852
-1,625
| -3% | -$93.3K | 0.57% | 40 |
|
|
2023
Q2 | $4.63M | Buy |
64,477
+3,550
| +6% | +$224K | 1.12% | 25 |
|
|
2023
Q1 | $4.22M | Buy |
60,927
+11,720
| +24% | +$703K | 1.11% | 23 |
|
|
2022
Q4 | $1.53M | Sell |
49,207
-6,205
| -11% | -$184K | 0.47% | 52 |
|
|
2022
Q3 | $2.03M | Buy |
55,412
+6,537
| +13% | +$255K | 0.63% | 41 |
|
|
2022
Q2 | $2.14M | Buy |
48,875
+7,506
| +18% | +$345K | 0.66% | 37 |
|
|
2022
Q1 | $2.64M | Buy |
41,369
+2,127
| +5% | +$152K | 0.67% | 36 |
|
|
2021
Q4 | $3.29M | Sell |
39,242
-8,965
| -19% | -$1.01M | 0.75% | 33 |
|
|
2021
Q3 | $7.83M | Buy |
48,207
+5,391
| +13% | +$876K | 1.9% | 14 |
|
|
2021
Q2 | $6.46M | Buy |
42,816
+3,607
| +9% | +$608K | 1.53% | 18 |
|
|
2021
Q1 | $6.81M | Buy |
39,209
+5,530
| +16% | +$1.05M | 1.79% | 14 |
|
|
2020
Q4 | $5.37M | Sell |
33,679
-958
| -3% | -$160K | 1.7% | 15 |
|
|
2020
Q3 | $5.52M | Sell |
34,637
-353
| -1% | -$63.7K | 2.01% | 15 |
|
|
2020
Q2 | $6.98M | Buy |
34,990
+11,402
| +48% | +$2.09M | 2.62% | 13 |
|
|
2020
Q1 | $3.65M | Buy |
23,588
+10,238
| +77% | +$1.03M | 1.68% | 19 |
|
|
2019
Q4 | $1.03M | Sell |
13,350
-1,446
| -10% | -$126K | 0.38% | 53 |
|
|
2019
Q3 | $1.49M | Sell |
14,796
-1,900
| -11% | -$221K | 0.67% | 37 |
|
|
2019
Q2 | $2.21M | Buy |
16,696
+2,292
| +16% | +$315K | 1.01% | 23 |
|
|
2019
Q1 | $2.18M | Buy |
14,404
+1,932
| +15% | +$301K | 1.05% | 25 |
|
|
2018
Q4 | $2.02M | Buy |
+12,472
| New | +$2.48M | 1.24% | 22 |
|
Other funds holding CTSO
AC
CM
SC
CBU
Sargent Investment Group's CTSO Position: Q2 2026 in Review
Sargent Investment Group increased its Cytosorbents Corp (CTSO) stake by 1.1% in Q2 2026, buying an estimated $3.1K and bringing the position to 27,788 shares worth $208K. The position accounts for 0.03% of the portfolio, ranked #260.
Sargent Investment Group first reported a position in CTSO in Q4 2018 and has held it in 31 quarters since. The position peaked at $7.83M in Q3 2021. 47 funds tracked by Wall St. Rank hold CTSO as of Q2 2026.
- Sargent Investment Group held 27,788 shares of Cytosorbents Corp worth $208K as of Q2 2026.
- Sargent Investment Group bought 293 Cytosorbents Corp shares in Q2 2026, an estimated $3.1K.
- Cytosorbents Corp made up 0.03% of Sargent Investment Group's portfolio in Q2 2026, its #260 holding.
- Sargent Investment Group first reported a position in Cytosorbents Corp in Q4 2018 and has held it in 31 quarters since.
- Sargent Investment Group's Cytosorbents Corp position peaked at $7.83M in Q3 2021.
- 47 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q2 2026.
Based on Sargent Investment Group's 13F filing for Q2 2026, filed 11 Aug 2026.